Updates are available Correction dated 2024-08-31
Click to view Correction: https://doi.org/10.1038/s41398-024-03064-x
-
Authors
Li, Danyang https://orcid.org/0000-0001-7470-6645
Pain, Oliver https://orcid.org/0000-0001-5680-3281
Fabbri, Chiara https://orcid.org/0000-0003-0276-7865
Wong, Win Lee Edwin https://orcid.org/0000-0001-6905-6449
Lo, Chris Wai Hang
Ripke, Stephan https://orcid.org/0000-0003-3622-835X
Cattaneo, Annamaria https://orcid.org/0000-0002-9963-848X
Souery, Daniel
Dernovsek, Mojca Z. https://orcid.org/0000-0001-5344-7007
Henigsberg, Neven https://orcid.org/0000-0002-5303-1834
Hauser, Joanna https://orcid.org/0000-0002-6621-3493
Lewis, Glyn https://orcid.org/0000-0001-5205-8245
Mors, Ole
Perroud, Nader
Rietschel, Marcella https://orcid.org/0000-0002-5236-6149
Uher, Rudolf https://orcid.org/0000-0002-2998-0546
Maier, Wolfgang
Baune, Bernhard T.
Biernacka, Joanna M. https://orcid.org/0000-0001-9350-4440
Bondolfi, Guido
Domschke, Katharina https://orcid.org/0000-0002-2550-9132
Kato, Masaki
Liu, Yu-Li https://orcid.org/0000-0001-7519-2965
Serretti, Alessandro
Tsai, Shih-Jen https://orcid.org/0000-0002-9987-022X
Weinshilboum, Richard https://orcid.org/0000-0002-4911-7985
,
McIntosh, Andrew M. https://orcid.org/0000-0002-0198-4588
Lewis, Cathryn M. https://orcid.org/0000-0002-8249-8476
-
Funding
Funding for this research was provided by:
Wellcome Trust (226770/Z/22/Z)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (MH124873)
- License Information
-
More Information
Article History
Received: 27 June 2023
Revised: 10 June 2024
Accepted: 18 June 2024
First Online: 19 July 2024
Change Date: 31 August 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41398-024-03064-x
Competing interests
: CML serves on the scientific advisory board for Myriad Neuroscience, and is a consultant for UCB. AS is or has been consultant/speaker for: Abbott, AbbVie, Angelini, AstraZeneca, Clinical Data, Boehringer, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, InnovaPharma, Italfarmaco, Janssen, Lundbeck, Naurex, Pfizer, Polifarma, Sanofi, and Servier. AMM has received research support from the Sackler Trust and speaker fees from Janssen and Illumina. MK has received grant funding from the Japanese Ministry of Health, Labor and Welfare, the Japan Society for the Promotion of Science, SENSHIN Medical Research Foundation, the Japan Research Foundation for Clinical Pharmacology and the Japanese Society of Clinical Neuropsychopharmacology and speaker’s honoraria from Sumitomo Pharma, Otsuka, Meiji-Seika Pharma, Eli Lilly, MSD K.K., Pfizer, Janssen Pharmaceutical, Shionogi, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical, Lundbeck Viatris Inc, Eisai Co., Ltd. and Ono Pharmaceutical and participated in an advisory/review board for Otsuka, Sumitomo Pharma, Shionogi and Boehringer Ingelheim. DS has received grant/research support from GlaxoSmithKline and Lundbeck; and served as a consultant or on advisory boards for AstraZeneca, Bristol Myers Squibb, Eli Lilly, Janssen, and Lundbeck. CF was a speaker for Janssen. NP is or has been consultant/speaker for: Takeda, Janssen and Lundbeck. All other authors report no biomedical financial interests or potential conflicts of interest.
: This was a secondary analysis of studies shared by investigators with the Psychiatric Genomics Consortium. Each original study had received ethics approval.
